Clinical and immunological characteristics of patients with 2009 pandemic influenza A (H1N1) virus infection after vaccination

Clinical Infectious Diseases

Volumn 51, Issue 9, 2010, Pages 1028-1032

  Liu, Wei ^a   De Vlas, Sake J ^e   Tang, Fang ^b   Ma, Mai Juan ^a   Wei, Mao Ti ^a   Liu, Li Juan ^a   Li, Zeng De ^b   Zhang, Lei ^a,d   Xin, Zhong Tao ^c   Tong, Yi Gang ^a   Jiang, Tao ^a   Zhang, Xiao Ai ^a   He, Cui ^a   Li, Chris ^f   Xu, Xiao Ning ^f   Yang, Hong ^a   Richardus, Jan Hendrik ^e   Cao, Wu Chun ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b Center for Diseases Control and Prevention of Chinese People's Armed Police Forces   (China)

^c CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

^d JISHOU UNIVERSITY   (China)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; OSELTAMIVIR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL COUNT; CELLULAR IMMUNITY; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; FEMALE; FEVER; HEADACHE; HUMAN; HUMORAL IMMUNITY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MALAISE; MALE; NONHUMAN; NOSE SMEAR; PANDEMIC INFLUENZA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SORE THROAT; THROAT CULTURE; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS LOAD; VIRUS MUTATION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; BLOOD; COHORT STUDIES; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LEUKOCYTES, MONONUCLEAR; MALE; NASOPHARYNX; VIRAL LOAD; YOUNG ADULT;

EID: 77958559416     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/656588     Document Type: Article

References (22)

1. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360:2605-2615.
2. Centers for Disease Control and Prevention. Update: infections with a swine-origin influenza A (H1N1) virus-United States and other countries, April 28, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:431-433.
3. Cao B, Li XW, Mao Y, et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med 2009; 361:2507-2517.
4. Chinese National Influenza Center. Influenza surveillance. http://www.cnic.org.cn/chn/show.php?content=323. Accessed 27 February 2010.
5. Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361:2414-2423.
6. Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010; 375:56-66.
7. World Health Organization. CDC protocol of realtime RTPCR for swine influenza A (H1N1). http://www.who.int/csr/resources/publications/swineflu/ CDCrealtimeRTPCRprotocol-20090428.pdf. Accessed 7 March 2010.
8. Zhou B, Donnelly ME, Scholes DT, et al. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and swine origin human influenza a viruses. J Virol 2009; 83:10309-10313.
9. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200:492-500.
10. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-943.
11. Barbey-Martin C, Gigant B, Bizebard T, et al. An antibody that prevents the hemagglutinin low pH fusogenic transition. Virology 2002; 294:70-74.
12. Yoden S, Kida H, Kuwabara M, Yanagawa R, Webster RG. Spin-labeling of influenza virus hemagglutinin permits analysis of the conformational change at low pH and its inhibition by antibody. Virus Res 1986; 4:251-261. (Pubitemid 16076731)
13. Knossow M, Gaudier M, Douglas A, et al. Mechanism of neutralization of influenza virus infectivity by antibodies. Virology 2002; 302:294-298. (Pubitemid 35373857)
14. Kida H, Webster RG, Yanagawa R. Inhibition of virus-induced hemolysis with monoclonal antibodies to different antigenic areas on the hemagglutinin molecule of A/seal/Massachusetts/1/80 (H7N7) influenza virus. Arch Virol 1983; 76:91-99. (Pubitemid 13025792)
15. To KK, Hung IF, Li IW, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010; 50:850-859.
16. Seo SH, Hoffmann E, Webster RG. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med 2002; 8:950-954. (Pubitemid 35033698)
17. De Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:1203-1207.
18. Osterlund P, Pirhonen J, Ikonen N, et al. Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to antiviral actions of interferons. J Virol 2010; 84:1414-1422.
19. Woo PC, Tung ET, Chan KH, Lau CC, Lau SK, Yuen KY. Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: implications for treatment strategies. J Infect Dis 2010; 201:346-353.
20. Matikainen S, Siren J, Tissari J, et al. Tumor necrosis factor alpha enhances influenza A virus-induced expression of antiviral cytokines by activating RIG-I gene expression. J Virol 2006; 80:3515-3522.
21. Veckman V, Osterlund P, Fagerlund R, Melen K, Matikainen S, Julkunen I. TNF-alpha and IFN-alpha enhance influenza-A-virus-induced chemokine gene expression in human A549 lung epithelial cells. Virology 2006; 345:96-104. (Pubitemid 43107575)
22. Singh A, Suresh M. A role for TNF in limiting the duration of CTL effector phase and magnitude of CD8 T cell memory. J Leukoc Biol 2007; 82:1201-1211. (Pubitemid 350133518)